Zeltia Group’s Yondelis to be Sold in Switzerland

MADRID, Feb 6 (Reuters) - Spanish biotechnology company Zeltia’s (ZEL.MC) Yondelis drug has received approval to be sold in Switzerland to treat soft tissue sarcoma (STS), the company said in a statement on Friday.

MORE ON THIS TOPIC